Asthma is a lung disease that makes everyday breathing exceedingly difficult for asthmatic patients. Breathing exercises, as well as emergency care medications and long-term asthma management prescriptions can be used for the treatment of asthma. But, thanks to intelligent drug advances, today’s asthma medicine treatment is extremely effective and has progressed from naturally occurring substances. Based on convincing medicines for alleviating severe bronchoconstriction, these asthmatic effects are considered usually preventable. The most effective asthma inhalers currently available include a corticosteroid and a long-acting 2 adrenoceptor agonist. Asthma can usually be controlled with medications to treat the symptoms of salbutamol and regulator inhalers to prevent health effects. Longer-acting inhalers (formoterol, salmeterol), as well as inhalant drugs, may be needed in extreme cases to keep aviation routes open (formoterol, salmeterol). Patients with specific genotypes in qualities involved with the function of beta-2 agonists or leukotriene inhibitors have had a few instances of reduced response in pharmacogenetic studies of drugs used to treat asthma.
REFERENCES
1.
D. E.
O’Donnell
et al, “Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD
,” Chest
, vol. 130
, no. 3
, pp. 647
–656
, 2006
.2.
A.
Anzueto
et al, “Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes
,” COPD J. Chronic Obstr. Pulm. Dis.
, vol. 6
, no. 5
, pp. 320
–329
, 2009
.3.
M.
Engelkes
, H. M.
Janssens
, J. C.
de Jongste
, M. C. J. M.
Sturkenboom
, and K. M. C.
Verhamme
, “Medication adherence and the risk of severe asthma exacerbations: a systematic review
,” Eur. Respir. J.
, vol. 45
, no. 2
, pp. 396
–407
, 2015
.4.
P. J.
Barnes
, “Drugs for asthma
,” Br. J. Pharmacol.
, vol. 147
, no. S1
, pp. S297
–S303
, 2006
.5.
E.
Kuipers
, M.
Wensing
, P.
de Smet
, and M.
Teichert
, “Self-management research of asthma and good drug use (SMARAGD study): a pilot trial
,” Int. J. Clin. Pharm.
, vol. 39
, no. 4
, pp. 888
–896
, 2017
.6.
M.
Nuijsink
, W. C. J.
Hop
, J. C.
de Jongste
, P. J.
Sterk
, and E. J.
Duiverman
, and C. S.
Group
, “Perception of bronchoconstriction: a complementary disease marker in children with asthma
,” J. Asthma
, vol. 50
, no. 6
, pp. 560
–564
, 2013
.7.
S.
Rubak
, A.
Høst
, L. B.
Christensen
, M. S.
Langfrits
, and R. W.
Thomsen
, “Validity of asthma diagnoses and patterns of anti-asthmatic drug use in a cohort of 2053 Danish children
,” Heal. Sci. reports
, vol. 1
, no. 9
, p. e77
, 2018
.8.
M. I.
Asher
et al, “Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys
,” Lancet
, vol. 368
, no. 9537
, pp. 733
–743
, 2006
.9.
P.
Santus
et al, “Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol
,” Eur. J. Intern. Med.
, vol. 26
, no. 6
, pp. 379
–384
, 2015
.10.
M. P.
Sovani
, C. I.
Whale
, and A. E.
Tattersfield
, “A benefit-risk assessment of inhaled long-acting β 2-agonists in the management of obstructive pulmonary disease
,” Drug Saf.
, vol. 27
, no. 10
, pp. 689
–715
, 2004
.11.
K. F.
Rabe
, R.
JORRES
, D.
Nowak
, N.
Behr
, and H.
Magnussen
, “Com {Jarison of the Effects of Salmeterol and Formoterol on Airway Tone and Responsiveness over 24 Hours in Bronchial Asthma
,” Am Rev Respir Dis
, vol. 147
, pp. 1436
–1441
, 1993
.12.
A.
Linden
, A.
Bergendal
, A.
Ullman
, B.-E.
Skoogh
, and C.-G.
Löfdahl
, “1. Linden A, Bergendal A, Ullman A, Skoogh B-E, Löfdahl C-G. Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism. Thorax. 1993;48(5):547–53. Salmete
,” Thorax
, vol. 48
, no. 5
, pp. 547
–553
, 1993
.13.
J. A.
Ohar
and J. F.
Donohue
, “Mono-and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD
,” in Seminars in respiratory and critical care medicine
, 2010
, vol. 31
, no. 03
, pp. 321
–333
.14.
A. J.
Apter
et al, “The effect of inhaled albuterol in moderate to severe asthma
,” J. Allergy Clin. Immunol.
, vol. 98
, no. 2
, pp. 295
–301
, 1996
.15.
“WebMD. (n.d.). Formoterol Fumarate Inhalation: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing. WebMD. https://www.webmd.com/drugs/2/drug-20787-998/formoterol-fumarate-inhalation/formoterol-solution-inhalation/details. - Google Search.”.
16.
R. N.
Brogden
and D.
Faulds
, “Salmeterol xinafoate
,” Drugs
, vol. 42
, no. 5
, pp. 895
–912
, 1991
.17.
“Long-Acting Beta-Agonists (LABAs) | AAAAI.”.
18.
E. H.
Ramsdale
, M. M.
Morris
, R. S.
Roberts
, and F. E.
Hargreave
, “Bronchial responsiveness to methacholine in chronic bronchitis: relationship to airflow obstruction and cold air responsiveness
.,” Thorax
, vol. 39
, no. 12
, pp. 912
–918
, 1984
.19.
P.
Montuschi
, “Role of leukotrienes and leukotriene modifiers in asthma
,” Pharmaceuticals
, vol. 3
, no. 6
, pp. 1792
–1811
, 2010
.20.
E. A.
Mellor
et al, “Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: functional distinction from CysLT1R
,” Proc. Natl. Acad. Sci.
, vol. 100
, no. 20
, pp. 11589
–11593
, 2003
.21.
J. W.
Ramsdell
, F. J.
Nachtwey
, and K. M.
Moser
, “Bronchial hyperreactivity in chronic obstructive bronchitis
,” Am. Rev. Respir. Dis.
, vol. 126
, no. 5
, pp. 829
–832
, 1982
.22.
R. J.
Horwitz
, K. A.
McGILL
, and W. W.
Busse
, “The role of leukotriene modifiers in the treatment of asthma
,” Am. J. Respir. Crit. Care Med.
, vol. 157
, no. 5
, pp. 1363
–1371
, 1998
.23.
K. L. E.
Hon
, T. F.
Leung
, and A. K. C.
Leung
, “Clinical effectiveness and safety of montelukast in asthma. What are the conclusions from clinical trials and meta-analyses?
,” Drug Des. Devel. Ther.
, vol. 8
, p. 839
, 2014
.24.
J. A.
Leff
et al, “Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction
,” N. Engl. J. Med.
, vol. 339
, no. 3
, pp. 147
–152
, 1998
.25.
26.
S. E.
Wenzel
and A. K.
Kamada
, “Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma
,” Ann. Pharmacother.
, vol. 30
, no. 7–8
, pp. 858
–864
, 1996
.27.
B. J.
O’Connor
, C.-G.
Löfdahl
, M.
Balter
, A.
Szczeklik
, L.-P.
Boulet
, and C. B.
Cairns
, “Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma
,” Respir. Med.
, vol. 101
, no. 6
, pp. 1088
–1096
, 2007
.28.
“HIGHLIGHTS OF PRESCRIBING INFORMATION.Merck.(n.d.). https://www.organon.com/product/usa/pi_circulars/s/singulair/singulair_pi.pdf. - Google Search.”.
29.
“Accolate (Zafirlukast): Uses, Dosage, Side Effects, Interactions, Warning.”.
30.
“Zyflo CR (Zileuton Extended Release Tablets): Uses, Dosage, Side Effects, Interactions, Warning.”.
31.
S. J.
Szefler
, “Leukotriene modifiers: What is their position in asthma therapy?
,” J. Allergy Clin. Immunol.
, vol. 102
, no. 2
, pp. 170
–172
, 1998
.32.
M. M.
del Giudice
et al, “Leukotriene modifiers in the treatment of asthma in children
,” Ther. Adv. Respir. Dis.
, vol. 3
, no. 5
, pp. 245
–251
, 2009
.33.
P. J.
Barnes
, “Inhaled corticosteroids
,” Pharmaceuticals
, vol. 3
, no. 3
, pp. 514
–540
, 2010
.34.
A. P.
Baptist
and R. C.
Reddy
, “Inhaled corticosteroids for asthma: are they all the same?
,” J. Clin. Pharm. Ther.
, vol. 34
, no. 1
, pp. 1
–12
, 2009
.35.
E.
Ihre
, O.
Zetterström
, E.
Ihre
, and B.
Hammarberg
, “Voice problems as side effects of inhaled corticosteroids in asthma patients—a prevalence study
,” J. Voice
, vol. 18
, no. 3
, pp. 403
–414
, 2004
.36.
P. J.
Barnes
, “Efficacy of inhaled corticosteroids in asthma
,” J. Allergy Clin. Immunol.
, vol. 102
, no. 4
, pp. 531
–538
, 1998
.37.
F. E. R.
Simons
and C. B. D. X. S.
Group
, “A comparison of beclomethasone, salmeterol, and placebo in children with asthma
,” N. Engl. J. Med.
, vol. 337
, no. 23
, pp. 1659
–1665
, 1997
.38.
P. J.
Sharek
, D.
Bergman
, and F. M.
Ducharme
, “Beclomethasone for asthma in children: effects on linear growth
,” Cochrane Database Syst. Rev.
, no. 3
, 1999
.39.
D. P.
Tashkin
, B.
Lipworth
, and R.
Brattsand
, “Benefit: risk profile of budesonide in obstructive airways disease
,” Drugs
, vol. 79
, no. 16
, pp. 1757
–1775
, 2019
.40.
D.
Gonzalez
and H.
Derendorf
, “Ciclesonide in the management of asthma
,” Clin. Med. Ther.
, vol. 1
, p. CMT
–S2133
, 2009
.41.
D. S.
Postma
, C.
Sevette
, Y.
Martinat
, N.
Schlösser
, J.
Aumann
, and H.
Kafé
, “Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening
,” Eur. Respir. J.
, vol. 17
, no. 6
, pp. 1083
–1088
, 2001
.42.
J. D.
Wolfe
, J. C.
Selner
, L. M.
Mendelson
, F. Hampel
Jr
, and A.
Schaberg
, “Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study
,” Clin. Ther.
, vol. 18
, no. 4
, pp. 635
–646
, 1996
.43.
E.
Verona
et al, “Fluticasone propionate in asthma: a long term dose comparison study
,” Arch. Dis. Child.
, vol. 88
, no. 6
, pp. 503
–509
, 2003
.44.
R. D.
Kempsford
, A.
Oliver
, J.
Bal
, L.
Tombs
, and D.
Quinn
, “The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing
,” Respir. Med.
, vol. 107
, no. 12
, pp. 1873
–1880
, 2013
.45.
A. J.
Oliver
et al, “Randomised trial of once-daily vilanterol in children with asthma on inhaled corticosteroid therapy
,” Respir. Res.
, vol. 17
, no. 1
, pp. 1
–11
, 2016
.46.
E. O.
Meltzer
, P.
Kuna
, H.
Nolte
, A. S.
Nayak
, and C.
Laforce
, “Mometasone furoate/formoterol reduces
asthma
deteriorations
and improves lung
function
,” Eur. Respir. J.
, vol. 39
, no. 2
, pp. 279
–289
, 2012
.47.
“DailyMed - QVAR-beclomethasone dipropionate aerosol, metered.”.
48.
“DailyMed - PULMICORT FLEXHALER-budesonide aerosol, powder.”.
49.
“DailyMed - ALVESCO-ciclesonide aerosol, metered.”.
50.
“DailyMed - FLOVENT DISKUS-fluticasone propionate powder, metered.”.
51.
“DailyMed - ARNUITY ELLIPTA-fluticasone furoate powder.”.
52.
“DailyMed - TRELEGY ELLIPTA-fluticasone furoate, umeclidinium bromide and vilanterol trifenatate powder.”.
53.
“DailyMed - ASMANEX-mometasone furoate inhalant.”.
54.
“DailyMed - DULERA-mometasone furoate and formoterol fumarate dihydrate aerosol.”.
55.
S. J.
Szefler
et al, “Significant variability in response to inhaled corticosteroids for persistent asthma
,” J. Allergy Clin. Immunol.
, vol. 109
, no. 3
, pp. 410
–418
, 2002
.56.
E. H.
Walters
, J. A. E.
Walters
, P. G.
Gibson
, and P.
Jones
, “Inhaled short acting beta2-agonist use in chronic asthma: regular versus as needed treatment
,” Cochrane Database Syst. Rev.
, no. 1
, 2003
.57.
C. K.
Billington
, R. B.
Penn
, and I. P.
Hall
, “β 2 Agonists
,” Pharmacol. Ther. Asthma COPD
, pp. 23
–40
, 2016
.58.
M.
Cazzola
, C. P.
Page
, P.
Rogliani
, and M. G.
Matera
, “Терапия с β2-агонисти–възможности при бронхообструктивни белодробни болести β 2-Agonist Therapy in Lung Disease
,” Am. J. Respir. Crit. Care Med.
, vol. 187
, 2013
.59.
D. M.
Williams
and B. K.
Rubin
, “Clinical pharmacology of bronchodilator medications
,” Respir. Care
, vol. 63
, no. 6
, pp. 641
–654
, 2018
.60.
A.
Grove
and B. J.
Lipworth
, “Tolerance with beta 2-adrenoceptor agonists: time for reappraisal
.,” Br. J. Clin. Pharmacol.
, vol. 39
, no. 2
, pp. 109
–118
, 1995
.61.
D. W.
Cockcroft
, C. P.
McParland
, S. A.
Britto
, V. A.
Swystun
, and B. C.
Rutherford
, “Regular inhaled salbutamol and airway responsiveness to allergen
,” Lancet
, vol. 342
, no. 8875
, pp. 833
–837
, 1993
.62.
W. O.
Spitzer
et al, “The use of β-agonists and the risk of death and near death from asthma
,” N. Engl. J. Med.
, vol. 326
, no. 8
, pp. 501
–506
, 1992
.63.
J. M.
Ramsahai
, P. M.
Hansbro
, and P. A. B.
Wark
, “Mechanisms and management of asthma exacerbations
,” Am. J. Respir. Crit. Care Med.
, vol. 199
, no. 4
, pp. 423
–432
, 2019
.64.
D. R.
Taylor
et al, “A new perspective on concepts of asthma severity and control
,” Eur. Respir. J.
, vol. 32
, no. 3
, pp. 545
–554
, 2008
.65.
M. R.
Sears
, “Epidemiology of asthma exacerbations
,” J. Allergy Clin. Immunol.
, vol. 122
, no. 4
, pp. 662
–668
, 2008
.66.
V. E.
Murphy
, P.
Gibson
, P. I.
Talbot
, and V. L.
Clifton
, “Severe asthma exacerbations during pregnancy
,” Obstet. Gynecol.
, vol. 106
, no. 5
Part 1, pp. 1046
–1054
, 2005
.67.
D. J.
Jackson
et al, “Quintupling inhaled glucocorticoids to prevent childhood asthma exacerbations
,” N. Engl. J. Med.
, vol. 378
, no. 10
, pp. 891
–901
, 2018
.68.
E. K.
Chu
and J. M.
Drazen
, “Asthma: one hundred years of treatment and onward
,” Am. J. Respir. Crit. Care Med.
, vol. 171
, no. 11
, pp. 1202
–1208
, 2005
.69.
H. S.
Baldwin
, M.
Dworetzky
, and N. J.
Isaacs
, “Evaluation of the steroid treatment of asthma since 1950
,” J. Allergy
, vol. 32
, no. 2
, pp. 109
–118
, 1961
.70.
M. M.
Zdanowicz
, “Pharmacotherapy of asthma
,” Am. J. Pharm. Educ.
, vol. 71
, no. 5
, 2007
.71.
C. A.
Bonham
, K. C.
Patterson
, and M. E.
Strek
, “Asthma outcomes and management during pregnancy
,” Chest
, vol. 153
, no. 2
, pp. 515
–527
, 2018
.72.
U.
Saleem
, M.
Usman
, F.
Anwar
, M. F.
Akhtar
, and B.
Ahmad
, “Pharmacological and toxicological evaluation of two anti-asthmatic polyherbal formulations
,” An. Acad. Bras. Cienc.
, vol. 92
, 2020
.73.
N. F.
Mendes
, C. P.
Jara
, E.
Mansour
, E. P.
Araújo
, and L. A.
Velloso
, “Asthma and COVID-19: a systematic review
,” Allergy, Asthma Clin. Immunol.
, vol. 17
, no. 1
, pp. 1
–12
, 2021
.74.
J. L.
Izquierdo
et al, “The impact of COVID-19 on patients with asthma
,” Eur. Respir. J.
, vol. 57
, no. 3
, 2021
.
This content is only available via PDF.
©2023 Authors. Published by AIP Publishing.
2023
Author(s)
You do not currently have access to this content.
